The rate of breakthrough of pneumocystis jiroveci pneumonia after transplant as a function of prophylaxis regimens.
Study #: IN06-01
Study Status: Published
Presentation(s)
2014, Tandem (Oral)
The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: A CIBMTR analysis.
Citation
Williams KM, Ahn KW, Chen M, Aljurf MD, Agwu AL, Chen AR, Walsh TJ, Szabolcs P, Boeckh MJ, Auletta JJ, Lindemans CA, Zanis-Neto J, Malvezzi M, Lister J, de Toledo Codina JS, Sackey K, Chakrabarty JLH, Ljungman P, Wingard JR, Seftel MD, Seo S, Hale GA, Wirk B, Smith MS, Savani BN, Lazarus HM, Marks DI, Ustun C, Abdel-Azim H, Dvorak CC, Szer J, Storek J, Yong A, Riches MR.
Bone Marrow Transplantation. 2016, Apr 01: 51(4): 51(4):573-580. doi: 10.1038/bmt.2015.316. Epub 2016, Jan 04. PMCID:PMC4823157.
PubMed
PMID: 26726945
Abstract